Details of the Drug-Related molecule(s) Interaction Atlas

US9493490, C Drug Info

US9493490, Example 3; BDBM258594; US9493490, C; US9493490, 6-(4-(1-aminoethyl)-2-fluorophenoxy)benzo[c][1,2]oxaborol-1(3H)-ol

Cross-matching ID

PubChem CID

90646682

TTD Drug ID

DMC1YR5

General Information of Drug (ID: DMC1YR5)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Beta-adrenergic receptor kinase 1 (ADRBK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9493490, E	DMFCIGE	N. A.	N. A.	Patented	[1]
US9493490, D	DMUVC25	N. A.	N. A.	Patented	[1]
BDBM50173306	DMSTD28	N. A.	N. A.	Patented	[2]
US9493490, L	DMJDTSN	N. A.	N. A.	Patented	[1]
PMID24210504C1o	DM4LEUT	Discovery agent	N.A.	Investigative	[3]
PMID21596927C101	DM7JRHB	Discovery agent	N.A.	Investigative	[4]
BetaARKct	DMN7DJ5	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Beta-adrenergic receptor kinase 1 (ADRBK1)	TTAZ3MN	ARBK1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Boron-containing small molecules. US9493490.
2	G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564.
3	Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6.
4	Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol. 2011 Aug;80(2):294-303.
5	Gene-mediated inhibition of the b-adrenergic receptor kinase: a new therapeutic strategy for heart failure. Minerva Cardioangiol. 2001 Dec;49(6):389-94.